BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology. Hosted on Acast. See acast.com/privacy for more information.
http://www.nature.com/npp/podcast/index.html
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder
Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results!
Hosted on Acast. See acast.com/privacy for more information.